Lipid raft alterations in aged-associated neuropathologies

Current Alzheimer Research

Volumn 13, Issue 9, 2016, Pages 973-984

  Marin, Raquel ^a   Fabelo, Noemí ^a   Fernández Echevarría, Cecilia ^a   Canerina Amaro, Ana ^a   Rodríguez Barreto, Deiene ^a   Quinto Alemany, David ^a   Mesa Herrera, Fátima ^a   Díaz, Mario ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Alzheimer s disease; Biomarkers; Cerebrospinal fluid; Lipid rafts; Lipids; Parkinson disease; Signalosomes

Indexed keywords

BIOLOGICAL MARKER; CELL MEMBRANE PROTEIN;

AGING; ALZHEIMER DISEASE; ARTICLE; CELL DAMAGE; DEGENERATIVE DISEASE; DISEASE COURSE; INTRACELLULAR SIGNALING; LIPID METABOLISM; LIPID RAFT; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOLECULAR STABILITY; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; ANIMAL; HUMAN; MEMBRANE MICRODOMAIN; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY;

AGING; ANIMALS; DISEASE PROGRESSION; HUMANS; MEMBRANE MICRODOMAINS; NEURODEGENERATIVE DISEASES;

EID: 84981499986     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160314150017     Document Type: Article

References (178)

1. Simons K, Vaz WL. Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct 33: 269-295 (2004).
2. Simons K, Gerl MJ. Revitalizing membrane rafts: New tools and insights. Nat Rev 11: 688-699 (2010).
3. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 8(2): 128-140 (2007).
4. Guirland C, Zheng JQ. Membrane lipid rafts and their role in axon guidance. Adv Exp Med Biol 621: 144-155 (2007).
5. Hanzal-Bayer MF, Hancock JF. Lipid rafts and membrane traffic. FEBS Lett 581(11): 2098-2104 (2007).
6. Korade Z, Kenworthy AK. Lipid rafts, cholesterol, and the brain. Neuropharmacology 55: 1265-1273 (2008).
7. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell 99: 129-140 (2007).
8. Schengrund CL. Lipid rafts: Keys to neurodegeneration. Brain Res Bull 82: 7-17 (2010).
9. Hannaoui S, Shim SY, Cheng YC, Corda E, Gilch S. Cholesterol balance in prion diseases and Alzheimer’s disease. Viruses 6(11): 4505-4535 (2014).
10. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, et al. Lipids as modulators of proteolytic activity of BACE: Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 280(44): 36815-36823 (2005).
11. Hur JY, Teranishi Y, Kihara T, Yamamoto NG, Inoue M, Hosia W, et al. Identification of novel γ-secretase-associated proteins in detergent-resistant membranes from brain. J Biol Chem 287(15): 11991-2005 (2005).
12. Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G. Mechanisms of disease: New therapeutic strategies for Alzheimer’s disease-targeting APP processing in lipid rafts. Nat Clin Pract Neurol 3(7): 374-382 (2007).
13. Rushworth JV, Hooper NM. Lipid rafts: Linking Alzheimer’s amyloid-b production, aggregation and toxicity at neuronal membranes. Int J Alzheimer’s Dis 2011: 603052-603064 (2010).
14. Hicks DA, Nalivaeva NN, Turner AJ. Lipid rafts and Alzheimer’s Disease: Protein-lipid interactions and perturbation of signaling. Front Physiol 3: 189 (2012).
15. Marin R, Marrero-Alonso J, Fernandez C, Cury D, Diaz M. Estrogen receptors in lipid raft signalling complexes for neuroprotection. Front Biosci (Elite Ed) 4: 1420-1433 (2012).
16. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. Lipid rafts mediate the synaptic localization of alphasynuclein. J Neurosci 24: 6715-6723 (2004).
17. Naslavsky N, Stein R, Yanai A, Friedlander G, Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J Biol Chem 272: 6324-6331 (1997).
18. Martín V, Fabelo N, Santpere G, Puig B, Marín R, Ferrer I, et al. Lipid alterations in lipid rafts from Alzheimer’s disease human brain cortex. J Alzheimers Dis 19: 489-502 (2010a).
19. Fabelo N, Martín V, Santpere G, Marín R, Torrent L, Ferrer I, et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol Med 17: 1107-18 (2011).
20. Fabelo N, Martín V, Marín R, Moreno D, Ferrer I, Díaz M. Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer disease and facilitates APP/BACE1 interactions. Neurobiol Aging 35: 1801-1812 (2014).
21. Diaz ML, Fabelo N, Marin R. Genotype-induced changes in biophysical properties of frontal cortex lipid raft from APP/PS1 transgenic mice. Front Physiol 3: 454-469 (2012).
22. Diaz M, Fabelo N, Martín V, Ferrer I, Gómez T, Marin R. Biophysical alterations in lipid rafts from human cerebral cortex associate with increased BACE1/AβPP interaction in early stages of Alzheimer’s disease. J Alzheimers Dis 43(4): 1185-1198 (2015).
23. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 327: 46-50 (2010).
24. Fabelo N, Martín V, Marín R, Santpere G, Aso E, Ferrer I, et al. Evidence for premature lipid raft aging in APP/PS1 doubletransgenic mice, a model of familial Alzheimer disease. J Neuropathol Exp Neurol 71: 868-881 (2012).
25. Fernandez-Echevarria C, Díaz M, Ferrer I, Canerina-Amaro A, Marin R. Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer’s disease. Neuroscience 278: 354-366 (2014).
26. Marin R, Rojo JA, Fabelo N, Fernandez CE, Diaz M. Lipid raft disarrangement as a result of neuropathological progresses: A novel strategy for early diagnosis? Neuroscience 245: 26-39 (2013).
27. Brown DA, London E. Structure and function of sphingolipid-and cholesterol-rich membrane rafts. J Biol Chem 275: 17221-17224 (2000).
28. Pike LJ. Lipid rafts: Bringing order to chaos. J Lipid Res 44: 655-667 (2003).
29. Paulick MG, Bertozzi CR. The glycosyphosphatidylinositol anchor: A complex membrane-anchoring structure for proteins. Biochemistry 47: 6991-7000 (2008).
30. Mukherjee A, Arnaud L, Cooper JA. Lipid-dependent recruitment of neuronal Src to lipid rafts in the brain. J Biol Chem 278: 40806-14 (2003).
31. Sato I, Obata Y, Kasahara K, Nakayama Y, Fukumoto Y, Yamasaki T, et al. Differential trafficking of Src, Lyn, Yes and Fyn is specified by the state of palmitoylation in the SH4 domain. J Cell Sci 122: 965-975 (2009).
32. Tsui-Pierchala B, Encinas M, Milbrandt J, Johnson EM. Lipid rafts in neuronal signalling and function. Trends Neurosci 25: 412-417 (2002).
33. Lajoie P, Goetz JG, Dennis JW, Nabi IR. Lattices, rafts, and scaffolds: Domain regulation of receptor signaling at the plasma membrane. J Cell Biol 185: 381-385 (2009).
34. Arcaro A, Aubert M, Espinosa del Hierro ME, Khanzada UK, Angelidou S, et al. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signaling. Cell Signal 19: 1081-1092 (2007).
35. Boulware MI, Kordasiewicz J, Mermelstein PG. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. J Neurosci 27: 9941-9950 (2007).
36. Marin R, Ramirez CM, Morales A, Gonzalez M, Alonso R, Diaz M. Modulation of Aβ-induced neurotoxicity by estrogen receptor alpha and other associated proteins in lipid rafts. Steroids 73: 992-996 (2008).
37. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiol Rev 88: 673-728 (2008).
38. Solis GP, Malaga-Trillo E, Plattner H, Stuermer CA. Cellular roles of the prion protein in association with reggie/flotillin microdomains. Front Biosci 15: 1075-1085 (2010).
39. Ariga T. Pathogenic role of ganglioside metabolism in neurodegenerative diseases. J Neurosci Res 92(10): 1227-1242 (2014).
40. Duyckaerts C, Dickson DW. Neuropathology of Alzheimer’s disease, Dickson DW, (Ed.), Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press pp. 47-65 (2003).
41. Lowe J, Mirra SS, Hyman B, Dickson DW. Ageing and Dementia. In: Love S, Louis DN, Ellison DW, Eds. Greenfield’s Neuropathology, London: Hodder Arnold, Vol. 1: Pp. 1031-1152 (2008).
42. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2(7): 492-501 (2001).
43. Spillantini MG, Schmidt ML, Lee VM, Trojanowski J, Jakes R, Goedert M. Alpha synuclein in Lewy bodies. Nature 388: 839-840 (1997).
44. Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson’s disease. J Neurol 250(3): 1-4 (2003).
45. Head BP, Patel HH, Insel PA. Interaction of membrane/lipid rafts with the cytoskeleton: Impact on signaling and function: Membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta 1838(2): 532-545 (2014).
46. Di Paolo G, Kim TW. Linking lipids to Alzheimer’s disease: Cholesterol and beyond. Nat Rev Neurosci 12: 284-296 (2011).
47. Schneider A, Rajendran L, Honsho M, Gralle M, Donnert G, Wouters F, et al. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J Neurosci 28(11): 2874-2882 (2008).
48. Bhattacharyya R, Barren C, Kovacs DM. Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts. J Neurosci 33(27): 11169-83 (2013).
49. Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer’s disease beta-amyloid production. Biochim Biophys Acta 1801: 860-867 (2010).
50. Ehehalt R, Michel B, De Pietri Tonelli D, Zacchetti D, Simons K, Keller P. Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas. Biochem Biophys Res Commun 293(1): 30-37 (2002).
51. Grimm MO, Tschäpe JA, Grimm HS, Zinser EG, Hartmann T. Altered membrane fluidity and lipid raft composition in presenilindeficient cells. Acta Neurol Scand Suppl 185: 27-32 (2006).
52. Matsumura N, Takami M, Okochi M, Wada-Kakuda S, Fujiwara H, Tagami S, et al. γ-Secretase associated with lipid rafts: Multiple interactive pathways in the stepwise processing of β-carboxylterminal fragment. J Biol Chem 289(8): 5109-5121 (2014).
53. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167: 953-960 (2004).
54. Askarova S, Yan X, Lee JC. Impacts of membrane biophysics in Alzheimer’s disease: From amyloid precursor protein processing to Ab peptide-induced membrane changes. Int J Alzheimer Dis 2011: 134971-134978 (2011).
55. Das U, Scott DA, Ganguly A, Koo EH, Tang Y, Roy S. Activityinduced convergence of APP and BACE-1 in acidic microdomains via an endocitosis-dependent pathway. Neuron 79: 447-460 (2013).
56. Von Arnim CA, Von Einem B, Weber P, Wagner M, Schwanzar D, Spoelgen R, et al. Impact of cholesterol level upon APP and BACE proximity and APP cleavage. Biochem Biophys Res Commun 370(2): 207-212 (2008).
57. Matsuzaki K. Formation of Toxic Amyloid Fibrils by Amyloid β-Protein on Ganglioside Clusters. Int J Alzheimers Dis 2011: 9504-956118 (2011).
58. Burke KA, Yates EA, Legleiter J. Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration. Front Neurol 4: 17-26 (2013).
59. Fantini J, Yahi N. Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: Common mechanisms in neurodegenerative diseases. Expert Rev Mol Med 12: e27-e34 (2010).
60. Yuyama K, Yanagisawa K. Sphingomyelin accumulation provides a favorable milieu for GM1 ganglioside-induced assembly of amyloid beta-protein. Neurosci Lett 481(3): 168-172 (2010).
61. Matsuzaki K1, Kato K, Yanagisawa K. Abeta polymerization through interaction with membrane gangliosides. Biochim Biophys Acta 1801(8): 868-877 (2010).
62. Barghorn S, Mandelkow E. Toward a Unified Scheme for the Aggregation of Tau into Alzheimer Paired Helical Filaments. Biochemistry 41: 14885-14896 (2002).
63. King ME, Gamblin TC, Kuret J, Binder LI. Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem 74(4): 1749-1757 (2000).
64. Ferrer I. Altered mitochondria, energy metabolism, voltagedependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer’s disease. J Bioenerg Biomembr 41(5): 425-431 (2009).
65. Akanda N, Tofighi R, Brask J, Tamm C, Elinder F, Ceccatelli S. Voltage-dependent anion channels (VDAC) in the plasma membrane play a critical role in apoptosis in differentiated hippocampal neurons but not in neural stem cells. Cell Cycle 7(20): 3225-3334 (2008).
66. Marin R, Ramírez CM, González M, González-Muñoz E, Zorzano A, Camps M, et al. Voltage-dependent anion channel (VDAC) participates in amyloid beta-induced toxicity and interacts with plasma membrane estrogen receptor alpha in septal and hippocampal neurons. Mol Membr Biol 24(2): 148-160 (2007).
67. Ramírez CM, González M, Díaz M, Alonso R, Ferrer I, Santpere G, et al. VDAC and ERalpha interaction in caveolae from human cortex is altered in Alzheimer’s disease. Mol Cell Neurosci 42(3): 172-183 (2009).
68. Pinto V, Messina A, Lane DJ, Lawen A. Voltage-dependent anionselective channel (VDAC) in the plasma membrane. FEBS Lett 584(9): 1793-1799 (2010).
69. Yoo BC, Fountoulakis M, Cairns N, Lubec G. Changes of voltagedependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer’s disease and Down syndrome. Electrophoresis 22(1): 172-179 (2001).
70. Martinez Z, Zhu M, Han S, Fink AL. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 46(7): 1868-1877 (2007).
71. Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, et al. A combinatorial code for the interaction of alphasynuclein with membranes. J Biol Chem 280(36): 31664-31672 (2005).
72. Stöckl M, Fischer P, Wanker E, Herrmann A. Alpha-synuclein selectively binds to anionic phospholipids embedded in liquiddisordered domains. J Mol Biol 375(5): 1394-1404 (2008).
73. Madine J, Doig AJ, Middleton DA. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry 45: 5783-5792 (2006).
74. Kim WS, Halliday GM. Changes in sphingomyelin level affect alpha-synuclein and ABCA5 expression. J Parkinsons Dis 2(1): 41-46 (2012).
75. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alphasynuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 37(4): 583-595 (2003b).
76. Angelova Pr, Horrocks MH, Klenerman D, Gandhi S, Abramov AY, Shchepinov MS. Lipid peroxidation is essential for α-synuclein-induced cell death. J Neurochem 133(4): 582-589 (2015).
77. Ronzitti G, Bucci G, Emanuele M, Leo D, Sotnikova TD, Mus LV, Soubrane CH, et al. Exogenous α-synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release. J Neurosci 34(32): 10603-10615 (2014).
78. Barceló-Coblijn G, Golovko MY, Weinhofer I, Berger J, Murphy EJ. Brain neutral lipids mass is increased in alpha-synuclein geneablated mice. J Neurochem 101(1): 132-141 (2007).
79. Golovko MY, Barceló-Coblijn G, Castagnet PI, Austin S, Combs CK, Murphy EJ. The role of alpha-synuclein in brain lipid metabolism: A downstream impact on brain inflammatory response. Mol Cell Biochem 326(1-2): 55-66 (2009).
80. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273(16): 9443-9449 (1998).
81. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: A review of secondary structure and function. J Lipid Res 33(2): 141-166 (1992).
82. Fallon L, Moreau F, Croft BG, Labib N, Gu WJ, Fon EA. Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J Biol Chem 277: 486-491(2002).
83. Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14: 3477-3492 (2005).
84. Kim KS, Kim JS, Park JY, Suh YH, Jou I, Joe EH, et al. DJ-1 Associates with lipid rafts by palmitoylation and regulates lipid rafts dependent endocytosis in astrocytes. Hum Mol Genet 22(823): 4805-4817 (2013).
85. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16: 678-690 (2007).
86. Esteves AR, Swerdlow RH, Cardoso SM. LRRK2, a puzzling protein: Insights into Parkinson’s disease pathogenesis. Exp Neurol 261: 206-216 (2014).
87. Valencia A, Reeves PB, Sapp E, Li X, Alexander J, Kegel KB, et al. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington’s disease. J Neurosci Res 88: 179-190 (2010).
88. Valencia A, Sapp E, Kimm JS, McClory H, Reeves PB, Alexander J, et al. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington’s disease. Hum Mol Genet 22(6): 1112-31 (2013).
89. Botto L, Cunati D, Coco S, Sesana S, Bulbarelli A, Biasini E, et al. Role of lipid rafts and GM1 in the segregation and processing of prion protein. PLoS One 9(5): e98344 (2014).
90. Puig B, Altmeppen H, Glatzel M. The GPI-anchoring of PrP: Implications in sorting and pathogenesis. Prion 8(1): 11-18 (2014).
91. Walsh KP, Kuhn TB, Bamburg JR. Cellular prion protein: A coreceptor mediating neuronal cofilin-actin rod formation induced by β-amyloid and proinflammatory cytokines. Prion 8(6): 375-80 (2014).
92. Watt NT, Griffiths HH, Hooper NM. Lipid rafts: Linking prion protein to zinc transport and amyloid-β toxicity in Alzheimer’s disease. Front Cell Dev Biol 2: 41-48 (2014).
93. Cui HL, Guo B, Scicluna B, Coleman BM, Lawson VA, Ellett L, et al. Prion infection impairs cholesterol metabolism in neuronal cells. J Biol Chem 289(2): 789-802 (2014).
94. Dillin A, Cohen E. Ageing and protein aggregation-mediated disorders: From invertebrates to mammals. Philos Trans R Soc Lond B Biol Sci 366(1561): 94-98 (2011).
95. Han X. Neurolipidomics: Challenges and developments. Front Biosci 12: 2601-2615 (2007).
96. Bennett SA, Valenzuela N, Xu H, Franko B, Fai S, Figeys D. Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer’s Disease. Front Physiol 4: 168-175 (2013).
97. Sastry PS. Lipids of nervous tissue: Composition and metabolism. Prog Lipid Res 24(2): 69-176 (1985).
98. Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE. Essential fatty acids in visual and brain development. Lipids 36(9): 885-895 (2001).
99. Crupi R, Marino A, Cuzzocrea S. n-3 fatty acids: Role in neurogenesis and neuroplasticity. Curr Med Chem 20(24): 2953-63 (2013).
100. Niemoller TD, Bazan NG. Docosahexaenoic acid neurolipidomics. Prostaglandins Other Lipid Mediat 91(3-4): 85-89 (2010).
101. Oster T, Pillot T. Docosahexaenoic acid and synaptic protection in Alzheimer’s disease mice. Biochim Biophys Acta 1801(8): 791-798 (2010).
102. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Azheimer’s disease. Neurochem Res 23: 81-88 (1998).
103. Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, Von Bergmann K, Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 41: 195-198 (2000).
104. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287: 2678-2688 (2012).
105. Ma DW. Lipid mediators in membrane rafts are important determinants of human health and disease. Appl Physiol Nutr Metab 32(3): 34-350 (2007).
106. Marin R, Diaz M. Neuronal lipid rafts perturbartions as key elements of early neurodegeneration: A challenge in the search of new tools for early diagnosis. In: Sillence D, Ed. Lipid Rafts, USA: Nova Science Publishers (2014), pp. 219-247 (2014).
107. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82: 239-259 (1991).
108. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 92: 171-182 (2005).
109. Wood WG, Schroeder F, Igbavboa U, Avdulov NA, Chochina SV. Brain membrane cholesterol domains, aging and amyloid betapeptides. Neurobiol Aging 23: 685-694 (2002).
110. Martin M, Dotti CG, Ledesma MD. Brain cholesterol in normal and pathological aging. Biochim Biophys Acta 1801(8): 934-944 (2010b).
111. Grimm MO, Zimmer VC, Lehmann J, Grimm HS, Hartmann T. The impact of cholesterol, DHA, and sphingolipids on Alzheimer’s disease. Biomed Res International 2013: 1-16 (2013).
112. Metzler-Baddeley C. A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer’s disease and Parkinson’s disease with dementia. Cortex 43: 583-600 (2007).
113. Ibarretxe-Bilbao N, Zarei M, Junque C, Marti MJ, Segura B, Vendrell P, et al. Dysfunctions of cerebral networks precede recognition memory deficits in early Parkinson’s disease. Neuroimage 57(2): 589-597 (2011).
114. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4): 389-404 (2006).
115. Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 97(1): 38-51 (2012).
116. Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer’s disease. Mol Membr Biol 23: 111-122 (2006).
117. Aso E, Lomoio S, López-González I, Joda L, Carmona M, Fernández-Yagüe N, et al. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer disease. Brain Pathol 22: 636-653 (2012).
118. Sonnino S, Aureli M, Mauri L, Ciampa MG, Prinetti A. Membrane lipid domains in the nervous system. Front Biosci (Landmark Ed) 20: 280-302 (2015).
119. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci USA 101: 2070-2075 (2004).
120. Barrier L, Fauconneau B, Noël A, Ingrand S. Ceramide and relatedsphingolipid levels are not altered in disease-associated brain regions of APP and APP/PS1 mouse models of Alzheimer’s disease: Relationship with the lack of neurodegeneration? Int J Alzheimers Dis 2011 920958-920968 (2011).
121. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, et al. Evidence that incidental Lewy body disease is presymptomatic Parkinson’s disease. Acta Neuropathol 115: 437-444 (2008).
122. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24: 197-211 (2003).
123. Stillwell W, Wassall SR. Docosahexaenoic acid: Membrane properties of a unique fatty acid. Chem Phys Lipids 126: 1-27 (2003).
124. Shaikh SR, Rockett BD, Salameh M, Carraway K. Docosahexaenoic acid modifies the clustering and size of lipid rafts and the lateral organization and surface expression of MHC class I of ELA4 cells. J Nutr 139: 1632-1639 (2009).
125. Vigh L, Escribá PV, Sonnleitner A, Sonnleitner M, Piotto S, Maresca B, et al. The significance of lipid composition for membrane activity: New concepts and ways of assessing function. Prog Lipid Res 44(5): 303-344 (2005).
126. Chapkin RS, Wang N, Fan YY, Lupton JR, Prior IA. Docosahexaenoic acid alters the size and distribution of cell surface microdomains. Biochim Biophys Acta 1778(2): 466-471 (2008).
127. Corsetto PA, Cremona A, Montorfano G, Jovenitti IE, Orsini F, Arosio P, et al. Chemical-physical changes in cell membrane microdomains of breast cancer cells after omega-3 PUFA incorporation. Cell Biochem Biophys 64(1): 45-59 (2012).
128. Shaikh SR, Teague H. N-3 fatty acids and membrane microdomains: From model membranes to lymphocyte function. Prostaglandins Leukot Essent Fatty Acids 87(6): 205-208 (2012).
129. Shaikh SR, Dumaual AC, Castillo A, LoCascio D, Siddiqui RA, Stillwell W, et al. Oleic and docosahexaenoic acid differentially phase separate from lipid raft molecules: A comparative NMR, DSC, AFM, and detergent extraction study. Biophys J 87: 1752-1766 (2004).
130. Munishkina LA, Fink AL. Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. Biochim Biophys Acta 1768(8): 1862-1885 (2007).
131. Kaiser RD, London E. Location of diphenylhexatriene (DPH) and its derivatives within membranes: Comparison of different fluorescence quenching analyses of membrane depth. Biochemistry 37(22): 8180-8190 (1998).
132. Lentz BR. Use of fluorescent probes to monitor molecular order and motions within liposome bilayers. Chem Phys Lipids 64(1-3): 99-116 (1993).
133. Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, et al. Lipid peroxidation as cause of nigral cell death in Parkinson’s disease. Lancet 2(8507): 639-640 (1986).
134. Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 53(3): S26-38 (2003).
135. Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64: 816-830 (2005).
136. Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, Selkoe DJ. Altered fatty acid composition of dopaminergic neurons expressing alpha synuclein and human brains with alpha-synucleinopathies. J Biol Chem 278(50): 49874-49881 (2003a).
137. Abbot SK, Jenner AM, Spiro AS, Batterham M, Halliday GM, Garner B. Fatty acid composition of the anterior cingulate cortex indicates a high susceptibility to lipid peroxidation in Parkinson’s disease. J Parkinson’s Dis 5: 175-185 (2015).
138. Brenna JT, Carlson SE. Docosahexaenoic acid and human brain development: Evidence that a dietary supply is needed for optimal development. J Hum Evol 77: 99-106 (2014).
139. Jicha GA, Markesbery WR. Omega-3 fatty acids: Potential role in the management of early Alzheimer’s disease. Clin Interv Aging 5: 45-61 (2010).
140. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128 (1991).
141. Casañas-Sánchez V, Perez JA, Fabelo N, Herrera-Herrera AV, Fernandez C, Marin R, et al. Addition of docosahexanoic acid, but not arachidonic acid, activates glutathione and thioredoxin antioxidant systems in murine hippocampal HT22 cells: Potential implications in neuroprotection. J Neurochem 131: 470-483 (2014).
142. Casañas-Sánchez V, Perez JA, Fabelo N, Quinto-Alemany D, Diaz M. Docosahexaenoic (DHA) modulates phospholipid-peroxide glutathione peroxidase (Gpx4) gene expression to ensure selfprotection from oxidative damage in hippocampal cells. Front Physiol 6(203): 1-11 (2015).
143. Gómez-Ramos A, Díaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 71(6): 863-870 (2003).
144. Gómez-Pinilla, F. Brain foods: The effects of nutrients on brain function. Nat Rev Neurosci 9: 568-578 (2008).
145. Alessandri JM, Guesnet P, Vancassel S, Astorg P, Denis I, Langelier B, et al. Polyunsaturated fatty acids in the central nervous system: Evolution of concepts and nutritional implications throughout life. Reprod Nutr 44: 509-538 (2004).
146. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: A complex association. Nat Clin Pract Neurol 5: 140-152 (2009).
147. Huhn S, Kharabian Masouleh S, Stumboll M, Villringer A, Witte AV. Components of a Mediterranean diet and their impact on cognitive functions in aging. Front Aging Neurosci 7(132): 1-10.
148. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5): 384-386 (2007).
149. Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H. Future directions in Alzheimer’s disease from risk factors to prevention. Biochem Pharmacol 88(4): 661-670 (2014).
150. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8): 734-746.
151. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer’s disease. BMC Med 8: 89-94 (2010).
152. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 36(5): 297-309 (2015).
153. Lerner A, Bagic A. Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov Disord 21(12): 2062-2067 (2008).
154. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Parkinson’s Progression Markers Initiativ. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10): 1277-1287 (2013).
155. Breen DP, Michell AW, Barker RA. Parkinson’s disease-the continuing search for biomarkers. Clin Chem Lab Med 49: 393-401 (2011).
156. de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes. Blood 102: 4336-4344 (2003).
157. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicel formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 262: 9412-9420 (1987).
158. Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: Current perspectives. Proteomics 8: 4083-4099 (2008).
159. Svensson KJ, Christianson HC, Wittrup A, Bourseau-Guilmain E, Lindqvist E, Svensson LM, et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. J Biol Chem 288(24): 17713-17724 (2013).
160. Coleman BM, Hill AF. Extracellular vesicles-Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases. Semin Cell Dev Biol S1084-9521(15)00034-8 (2015).
161. Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: Vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol 3: 124-130 (2012).
162. Lin J, Li J, Huang B, Liu J, Chen X, Chen XM, et al. Exosomes: Novel Biomarkers for Clinical Diagnosis. Sci World J 2015: 657086-657113 (2015).
163. Perez-Gonzalez R, Gauthier SA, Kumar A, Levy E. The exosome secretory pathway transports amyloid precursor protein carboxylterminal fragments from the cell into the brain extracellular space. J Biol Chem 287(51): 43108-43115 (2012).
164. Chivet M, Hemming F, Pernet-Gallay K, Fraboulet S, Sadoul R. Emerging role of neuronal exosomes in the central nervous system. Front Physiol 3: 145-155 (2012).
165. Yuyama K, Sun H, Usuki S, Sakai S, Hanamatsu H, Mioka T, et al. A potential function for neuronal exosomes: Sequestering intracerebral amyloid-β peptide. FEBS Lett 589(1): 84-88 (2015).
166. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Möbius W, Hoernschemeyer J, et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 278(13): 10963-10972 (2003).
167. Subra C, Laulagnier K, Perret B, Record M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 89(2): 205-212 (2007).
168. Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl 9(3-4): 358-367 (2015).
169. Ranghino A, Dimuccio V, Papadimitriou E, Bussolati B. Extracellular vesicles in the urine: Markers and mediators of tissue damage and regeneration. Clin Kidney J 8(1): 23-30 (2015).
170. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33(9): 1717-1723 (2008).
171. Fonteh AN, Chiang J, Cipolla M, Hale J, Diallo F, Chirino A, et al. Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer’s disease. J Lipid Res 54(10): 2884-2897 (2013).
172. Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer’s disease as identified by biomarkers. Neuromol Med 13(1) 37-43 (2011).
173. Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med 10: 5-18 (2012).
174. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer’s disease. Biomark Med 4(1): 27-36 (2010).
175. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441(7092): 513-517 (2006).
176. Cho DH, Nakamura T, Fang J, Cieplak P, Godzik A, Gu Z, et al. Snitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324(5923): 102-105 (2009).
177. Halloran M, Parakh S, Atkin JD. The role of s-nitrosylation and sglutathionylation of protein disulphide isomerase in protein misfolding and neurodegeneration. Int J Cell Biol 2013: 797914-797925 (2013).
178. Kwak YD, Wang R, Li JJ, Zhang YW, Xu H, Liao FF. Differential regulation of BACE1 expression by oxidative and nitrosative signals. Mol Neurodegener 6: 17-228 (2011).